ArticleBMC cancer2017

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.

Sakura Iizumi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.